Digital Medicine Society (DiMe)

🏥 Are you interested in rapidly advancing the establishment of a thriving hospital-at-home ecosystem, demonstrating impact and value at scale? 💡 If so, join our new project, “Advancing a Sustainable Hospital-at-Home Ecosystem at Scale”! We are convening leading hospitals, payors, and digital health innovators to pave the way for hospital-at-home care models that are both scalable and sustainable to deliver outsized benefits to patients and health systems alike. 📊 Alignment and benchmarks are needed to define performance criteria for the hospital-at-home tech stack so that innovators can maximize return on investment for this patient-centric model to successfully transfer and implement the hospital care model to the home with coordinated efforts. 🤝 Partner with us as we establish industry-vetted resources to support creating and implementing a digitally enabled hospital-at-home model with leading hospitals, payors, and digital health innovators. 🔗 Share your interest here: https://lnkd.in/dGVabrx7

🤖 Is your healthcare organization grappling with the implementation of Artificial intelligence (AI) technologies? If so, you’re not alone! 🏥 The U.S. healthcare ecosystem continues to struggle with implementing innovations while navigating existing healthcare infrastructure and norms. 🚨 NOW is the time to join DiMe’s “The Playbook: Implementing AI in Healthcare” project to support the seamless integration of #AI into patient care, streamlining processes, enhancing clinical decision-making, and improving outcomes. 🤝 By joining this project, you’ll collaborate with industry leaders, regulatory bodies, and researchers across the field to outline the critical steps of AI implementation and optimization. Together, we can bridge the gap between cutting-edge #technology and practical implementation, ensuring that AI's benefits reach every patient, caregiver, and healthcare professional! 🔗 Share your interest in joining the project here: https://bit.ly/3xtKqGQ

🧠 Amid a shortage of mental health providers, millions of adult patients are suffering from major depressive disorder (MDD), yet few evidence-based solutions without side effects exist. 💊 Click Therapeutics, Inc. is charting a new course by setting standards for bringing innovative software products to market as prescription medical treatments. 💡 Recognizing the urgent need for evidence-based solutions to address the shortage of mental health providers and the prevalence of MDD, Click Therapeutics developed Rejoyn, a groundbreaking digital therapeutic for the treatment of MDD symptoms. 🔬 But Click didn't just settle for a traditional approach. They took a bold step by engaging with the FDA to understand the rigorous evidence requirements necessary for demonstrating Rejoyn's safety and clinical performance – similar to the standards set for pharmaceutical drugs. ⚒️ Using this non-traditional approach, Click identified the specific requirements and specifications tailored to Rejoyn's unique capabilities in MDD for the 510(k) regulatory pathway. This case study showcases the FDA's nimbleness in regulating innovative treatments and Click's dedication to evidence rigor and market innovation! 🔗 Explore the full case study and discover how Click Therapeutics is changing lives through targeted digital interventions: https://bit.ly/3Kp3NUl

⚕️ Last week, we unveiled an exciting opportunity for you to help shape the future of AI in healthcare. 📘 DiMe’s newest project, “The Playbook: Implementing AI in Healthcare,” is more than just a project; it's a shared mission to use AI to drive transformative change throughout #healthcare settings. 🤝 By becoming a project partner, you'll help lead the way as we overcome the barriers hindering the widespread adoption of AI in healthcare. Together, we'll create a comprehensive roadmap that addresses the real-world challenges of implementing AI in clinical settings, from regulatory compliance to patient safety and equity. 💡 Your expertise and insights will be invaluable as we chart a new course toward a future where AI revolutionizes patient care, empowers healthcare professionals, and saves lives. 🔗 Share your interest in joining the project here: https://bit.ly/3xtKqGQ

🌐 Virtual care solutions that go far beyond simply trying to replicate the in-person visit are thriving. 🩺 Working in today’s healthcare ecosystem, it’s critical to understand virtual first care (V1C) and the value it brings to the future of innovation. And the V1C Coalition by DiMe has developed an easy, free way for you to learn everything you need to know. 🎓 The “Capturing the Value of V1C for Healthcare Delivery” course clarifies the difference between "virtual-first care" and "telehealth/telemedicine" - a common, but critical misunderstanding in our industry. It also teaches you about: ▪️ The revenue cycle management and reimbursement pathways for V1C. ▪️ How to integrate V1C into existing systems ▪️ The future of value-based care and how it fits into virtual care environments 📚 Enroll at no cost today to learn more: https://bit.ly/3VjfIbl

🚨🚨🚨 Last call to register! Our FREE public meeting led by FDA and the Digital Medicine Society (DiMe) starts tomorrow! Join us on June 26 and June 27, from 11 a.m. to 3 p.m. ET each day. We’ll explore how patient-generated health data (PGHD) can advance remote clinical trial #data collection and facilitate high-quality clinical outcome assessment. 👥 During this 2-day public meeting, you will have the opportunity to learn about and discuss: ▪️ How to implement PGHD throughout the total product life cycle development of medical device development ▪️ Tangible case examples of how PGHD has informed medical devices and can improve return on investment ▪️ How PGHD can help improve health equity by promoting inclusivity in research studies ▪️ Case-based learning on the use of PGHD for medical device developers, scientists, and patients 🔗 Register today and join us for this unique opportunity to learn alongside industry leaders and contribute to future work on resources to advance the use of PGHD in clinical research and regulatory science. https://lnkd.in/ej93__-2 AbbVie ActiGraph Advanced Research Projects Agency for Health (ARPA-H) Bellerophon Therapeutics Clario COPD Foundation Empatica Evidation FasterCures FDA Google HITea With Grace Jackson Heart Study, Koneksa Medable, Inc The Michael J. Fox Foundation for Parkinson's Research National Organization for Rare Disorders Netherlands Organisation for Applied Scientific Research TNO The Light Collective Tidepool Verily VivoSense, Inc. Walgreens Boots Alliance White House Office of Science and Technology Policy WHOOP

🧠 Mental health needs are skyrocketing, yet access to quality support remains a significant challenge. Woebot Health has made it their mission to make behavioral health accessible to patients. 💬 Their fully automated platform offers personalized, evidence-based support through AI-powered, chat-based conversations, helping individuals cope with anxiety and depression anytime, anywhere. 🤝 What sets Woebot Health apart is their commitment to collaboration, regulatory engagement, rigorous research, and quality standards. Through open communication and correspondence with the FDA, they are exploring novel pathways to provide mental health support. Their ISO:13485-certified quality management system ensures top-notch software development and reliable support. 👥 With products like Woebot for Adults, Adolescents, and Maternal Health, they address diverse mental health needs and have provided 74M minutes of non-human emotional support to 1.5M individuals! 🔗 Click below to read the full case study on how Woebot Health is transforming mental health accessibility:https://lnkd.in/dueGD-sz

🔍 Are you a health innovator working to integrate cutting-edge digital technologies into clinical trials? Do you need clear evidence of ROI to justify investment in novel digital strategies? 👀 If so, look no further. 📈 The adoption of digital endpoints in clinical trials is increasing. This is evidenced by the FDA recently qualifying the first digital endpoint for clinical trials under the Medical Device Development Tools program as well as by our own research with the Tufts Center for the Study of Drug Development and industry leaders at Johnson & Johnson, Roche, Genentech, UCB, Bayer, Takeda Oncology, and MindMed that demonstrated the use of digital endpoints in trials can generate a substantial return on investment through efficiencies 🛠️ Our newest project, "Building the Business Case for Digital Endpoints," is aimed to support you by developing standardized frameworks for measuring the value digital endpoints generate across drug development, medical devices, digital therapeutics, and other clinical research areas. 📊 This new project will establish benchmarks, best practices, and ROI models to equip you with data-driven tools to make a strong business case tailored to your company's priorities. 🔗 Learn more here: https://lnkd.in/ej6YnfSi 🌐 If you would like to join one of DiMe’s other upcoming projects, you can find them here: https://lnkd.in/eTedsmbk

🧠 Digital health technologies (DHTs) are becoming increasingly recognized as optimal instruments for objectively assessing patient status in Alzheimer’s disease and related dementias (ADRD). These digital health technologies (DHTs) can serve as screening tools or diagnostic aids to track symptoms and disease progression. 📖 DATAcc by DiMe recently published a comprehensive landscape review in Springer Nature Group's, The Journal of Prevention of Alzheimer’s Disease, identifying over 100 digital health technologies being used for assessment and monitoring in ADRD populations. 🤝 This multi-stakeholder collaboration, involving experts from academia, industry, clinical practice, and patient advocacy groups, surveyed 20 years of peer-reviewed literature and community input to catalog technologies like wearable sensors, smartphone/tablet apps, smart home setups, and more. This collaborative review highlights digital health technologies’ vast potential to enable: ✅ Earlier detection of cognitive decline ✅ Continuous remote monitoring of disease progression ✅ Measurement of treatment response ✅ Improved clinical trial endpoints Whether it is an app evaluating memory and speech or sensors tracking mobility and gait - DHTs are transforming ADRD care and research! 📚 Read our findings here: https://lnkd.in/eUQqqYSV

❓ Are you ready to seize new market opportunities, pave the way for hospital-at-home technology adoption, and ignite ecosystem-wide innovation? 🚨 If so, you don’t want to miss DiMe’s upcoming project. 🏥 “Advancing a Sustainable Hospital-at-Home Ecosystem at Scale” will provide action-oriented, open-access resources to ensure that the promise of digitally enabled hospital-at-home results in cost savings, improved resource management, increased patient satisfaction, and better #health outcomes for the greatest number of patients. This project will: ▪️ Ensure the persistence of early success in delivering hospital-at-home care ▪️ Establish reimbursement clarity around hospital-at-home care models with the highest impact, encouraging payors outside the Medicare program to participate ▪️ Drive broader and more efficient adoption by clarifying the #tech stack necessary and best practices to deliver hospital-at-home care 📅 Don’t miss your chance to join this project. Share your interest here: https://lnkd.in/dGVabrx7